SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
(Amendment No. *)
Under the Securities Exchange Act of 1934
Lantern Pharma Inc.
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
November 8, 2022
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)
CUSIP No. 51654W101
NAMES OF REPORTING PERSONS
ProPhase Labs, Inc.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
(a) ☐ (b) ☐
SEC USE ONLY
CITIZENSHIP OR PLACE OF ORGANIZATION
SOLE VOTING POWER
SHARED VOTING POWER
SOLE DISPOSITIVE POWER
SHARED DISPOSITIVE POWER
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ☐
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
TYPE OF REPORTING PERSON (see instructions)
|(1)||Based on 10,857,040 shares outstanding as of November 1, 2022 according to the quarterly report on Form 10-Q filed by the Issuer with the Securities and Exchange Commission on November 7, 2022.|
(a) Name of Issuer:
Lantern Pharma Inc. (the “Issuer”)
(b) Address of Issuer’s Principal Executive Offices:
1920 McKinney Avenue, 7th Floor Dallas, Texas 75201
(a)-(c) Name, Address and Citizenship of Reporting Persons
ProPhase Labs, Inc.
711 Stewart Ave, Suite 200
Garden City, New York 11530
Place of Incorporation: Delaware
(d) Title of Class of Securities
Common Stock, $0.0001 par value per share (“Common Stock”)
(e) CUSIP Number
Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
Item 4. Ownership.
(a) Amount Beneficially Owned:
Please refer to items 5-9 of the cover pages attached hereto for the amounts beneficially owned by the reporting persons as of November 21, 2022.
(b) Percent of Class
Please refer to item 11 of the cover pages attached hereto
(c) Number of shares as to which such person has:
Please refer to items 5-8 of the cover pages attached hereto
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☐
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
Item 8. Identification and Classification of Members of the Group.
Item 9. Notice of Dissolution of Group.
Item 10. Certification.
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|Date: November 21, 2022||PROPHASE LABS, INC.|
|By:||/s/ Ted Karkus|
|Title:||Chairman of the Board and Chief Executive Officer|